Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
One in 12 docs took payments from opioid makers; hospitals cut use of Isuprel and Nitropress after price hikes; AI helping develop ALS drugs
About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1
Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
More older Americans are taking at least three psychiatric drugs; Marathon to pause launch of Emflaza; Aetna and Humana call off deal
Online doctors prescribe drugs without adequate warnings; House lawmakers to discuss Part B proposal; obesity drugs struggle for market share
CDC issues new opioid prescribing guidelines; Sanofi partnership will focus on oral-drug development; MannKind hires Amgen exec
In this webinar Zitter Health Insights will deconstruct script abandonment and provide you key findings around the impact on patient outcomes.
Researchers found that a signed promise not to prescribe lowered prescriptions by around 20%.
The drugstore chain says it has cut off over-prescribers of tightly controlled medications.
Internists and small-office practitioners are also more likely to prescribe branded drugs than their professional peers.
Monthly Prescribing Reference's first revamp in three years includes new features which have already attracted new users. VP of product development Tammy Chernin told MM&M these changes are just the beginning.
The DIA and the Healthcare Businesswomen's Association formalized a multi-year partnership, and GSK began shipping vaccine for the 2012-2013 flu season
Three out of five doctors are now using technology to better communicate with patients, a MedPage Today survey has found, and two-fifths say patients are generally more informed than they were five years ago.
A new study by Surescripts, the nation's largest e-prescription network, suggests that saving patients the trouble of toting a prescription to a store increases the likelihood that they will get it filled and take their meds.
Women are simultaneously given more drugs than men and undertreated, according to a study Medco and the Society of Women's Health Research.
A fifth of consumers have asked their doctor to prescribe a drug they learned about through advertising, and fully two-thirds have received free samples of prescription drugs from their doctor - but they worry about the industry's influence on physicians, according to a Consumer Reports survey.
A federal appeals court will hear oral arguments regarding Maine's prescription data law, which allows physicians to "opt-out" of commercially traded data pertaining to their prescribing habits.
Abbott Labs' cholesterol drug Niaspan is growing prescription share nicely after a clinical trial highlighted its potential as part of a one-two punch in reducing plaque. Now, the company says, it is considering how best to capitalize on the data.
The nature and amount of press coverage is often a key factor in assessing how clinical trial results impact a product's prescription trends. In the case of the ARBITER 6-HALTS trial, Merck's cholesterol franchise has benefited from largely balanced coverage, somewhat limiting damage to lipid drugs Zetia and Vytorin.
As the number of FDA-approved fibromyalgia therapies has grown, so has patient hope. However, the condition is still not well understood by the medical community overall, hampering uptake of branded drugs approved for the disorder.
A survey of patients at Harvard's Dana-Farber Cancer Institute found that 11% said ads for cancer-related drugs had made them less confident in their providers' judgment.
Can pharma companies really predict the success of new product launches? Patrick Howie and Mike Luby report on how pharmas can hone in on physicians' actual prescribing behavior versus stated intentions